Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Marmara University
With
Schering-Plough
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient age \>18 years old
Histopathological diagnosis of high grade glioma (anaplastic astrocytoma or anaplastic oligodendroglioma or anaplastic oligoastrocytoma or glioblastoma multiforme)
Progression after standard dose (D1-5/28 days)temozolomide either during recurrence or adjuvant treatment approved in Magnetic Resonance imaging
Karnofsky Performance Status scale \>/=50 (due to brain pathology)
Adequate hematological, renal and hepatic function
Patients willing to participate in the study and signing the informed consent
You may not be if
Karnofsky Performance Status scale \<50
Female patients with pregnancy or with suspicion of pregnancy. Patients with fertility will be warned for appropriate contraception during the study
Patients not suitable for follow-up
Clareo Health | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
